Based on these data, we propose considering LADY in patients meeting the following criteria: (1) does not require insulin for glycemic control, (2) present in youth (age <29 years), (3) personal/family history of autoimmune diseases or diabetes (not specific to LADY); (4) acute symptoms of polydipsia, polyuria, or weight loss; and (5) low serum C-peptide (<0.8 ng/mL). This evidence concerns the gene INS and autoimmune disease.